ViewsML Nabs $4.9M for AI That Virtually Stains Human Tissue

VANCOUVER, British Columbia – April 20, 2026 – Vancouver-based startup ViewsML has closed an oversubscribed $4.9 million seed funding round to accelerate a technology that could fundamentally change how diseases are diagnosed and treated. The company’s artificial intelligence platform generates detailed biomarker information directly from standard pathology images, creating "virtual stains" without the need for the time-consuming and resource-intensive laboratory processes that have been standard for decades.

The funding round, led by Wittington Ventures, attracted significant strategic interest, with new investments from Continuum Health Ventures and the prestigious Mayo Clinic. The participation of these key players, alongside repeat investors RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund, signals strong market confidence in ViewsML's mission to transform tissue analysis from a physical lab procedure into a rapid, scalable software solution. The capital is earmarked for accelerating commercialization, expanding strategic partnerships, and advancing the clinical validation required to bring this technology into widespread use.

Strategic Capital Signals a New Era in Digital Diagnostics

The composition of ViewsML’s new investors provides more than just financial fuel; it offers a strategic ecosystem poised to accelerate the company's growth. Lead investor Wittington Ventures, a $500M firm backed by the holding company for Canadian giants like Loblaw and Shoppers Drug Mart, has a dedicated "Connected Health" investment thesis. The firm seeks to back companies leveraging deep scientific expertise and data to drive systemic change in healthcare, making ViewsML a natural fit.

“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches,” said Zeeshan Ali, Partner, Wittington Ventures. “Virtual staining has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease – driving faster insights and improved patient outcomes.”

The involvement of Mayo Clinic is particularly significant. As a world-leading medical institution with a robust internal AI strategy, its investment serves as a powerful endorsement. Mayo Clinic has already established major partnerships to create AI platforms for digital pathology and drug discovery, supporting over 250 internal AI projects. Their recent investment focus has heavily favored diagnostics, aiming to leverage AI for earlier disease detection and optimized treatment pathways for complex conditions like cancer. This alignment suggests a deep, practical interest in integrating ViewsML’s technology into real-world clinical workflows.

Disrupting a Decades-Old Bottleneck in Pathology

At the heart of ViewsML’s innovation is a direct challenge to the "critical bottleneck" of traditional immunohistochemistry (IHC). For decades, IHC has been the gold standard for identifying proteins and other biomarkers in tissue samples, a crucial step in cancer diagnosis and treatment planning. However, this "legacy approach" is a multi-step, manual process involving tissue fixation, sectioning, and chemical staining that can take days or even weeks to yield results. It is labor-intensive, costly, and consumes precious, often irreplaceable, biopsy tissue.

ViewsML proposes to bypass this entire workflow. Its AI-driven platform analyzes standard H&E (hematoxylin and eosin) stained slides—the most common type of pathology slide—and computationally predicts the presence, location, and quantity of specific biomarkers at a cellular level. This process of virtual staining turns a weeks-long lab procedure into a software analysis that takes minutes. The company is compiling these AI models into what it calls the "world’s first virtual biomarker library," an expanding digital toolkit that can be applied to pathology images on demand.

“We’re building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures and work with Mayo Clinic to accelerate that vision,” said Kenneth To, CEO, ViewsML. “By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”

This approach not only promises unprecedented speed but also conserves tissue. Since multiple virtual stains can be generated from a single digital image, it eliminates the need to cut multiple thin sections from a small biopsy, preserving the sample for further testing or research.

The Path from Promising AI to Clinical Standard

While the promise is immense, the road to clinical adoption requires navigating a competitive landscape and rigorous regulatory hurdles. The digital pathology space includes established AI players like Paige.AI and PathAI, which have focused on developing AI tools to assist pathologists in interpreting physically stained slides for cancer detection and grading. ViewsML differentiates itself by aiming to replace the physical staining process itself, representing a more fundamental disruption to the existing workflow.

A significant portion of the new funding is dedicated to "advancing clinical validation of virtual biomarker panels." This involves large-scale studies to prove that the virtual stains generated by the AI are as accurate and reliable as the results from traditional IHC. The collaboration with partners like Mayo Clinic will be instrumental in conducting these validation studies and gathering the robust data required for regulatory submission to bodies like the U.S. Food and Drug Administration (FDA).

The regulatory pathway for AI-based diagnostic software is complex and evolving. The FDA has established frameworks for "Software as a Medical Device" (SaMD) that require stringent evidence of clinical performance, safety, and adherence to "Good Machine Learning Practice." Successfully navigating this process will be a critical milestone for ViewsML on its path to commercialization.

Unlocking the Future of Precision Medicine

The ultimate impact of ViewsML's technology lies in its potential to accelerate the delivery of precision medicine and improve patient care. By dramatically shortening the time to diagnosis, clinicians can make faster, more informed treatment decisions. In oncology, where the presence of biomarkers like PD-L1 or HER2 determines eligibility for life-saving targeted therapies and immunotherapies, a delay of weeks can have serious consequences. Reducing that wait time to minutes could directly translate to better patient outcomes.

Furthermore, the ability to generate a comprehensive biomarker profile from a single, small tissue sample opens up new possibilities for highly personalized treatment plans. It allows for a deeper understanding of a patient’s unique disease biology, enabling more tailored therapeutic strategies. This is particularly vital as medicine moves towards combining multiple biomarkers to predict treatment response more accurately.

The platform's potential extends beyond cancer. As noted by investors, it could accelerate research in complex fields like neurodegenerative diseases, where biomarker discovery has been challenging. For pharmaceutical companies, the technology offers a way to speed up drug discovery and streamline clinical trials by more efficiently identifying patient cohorts and evaluating therapeutic efficacy, ultimately bringing new medicines to patients faster. By transforming a physical, resource-limited process into scalable software, ViewsML is positioned to unlock the vast biological value hidden within existing pathology data and help redefine the future of diagnostics.